研究单位：[1]Janssen Research & Development, LLC[2]Arizona Oncology Associates, PC - HAL,Goodyear,Arizona,United States,85395[3]Yuma Regional Medical Center,Yuma,Arizona,United States,85364[4]City of Hope Long Beach Elm,Long Beach,California,United States,90813[5]University of California, Irvine,Orange,California,United States,92868[6]Rocky Mountain Cancer Centers,Lone Tree,Colorado,United States,80124[7]Cancer Specialists of North Florida,Jacksonville,Florida,United States,32256[8]University Cancer & Blood Center, LLC,Athens,Georgia,United States,30607[9]East Jefferson General Hospital,Metairie,Louisiana,United States,70006[10]Maryland Oncology Hematology, PA,Columbia,Maryland,United States,21044[11]Henry Ford Hospital,Detroit,Michigan,United States,48202[12]Minnesota Oncology Hematology, P.A.,Edina,Minnesota,United States,55435[13]Mayo Clinic,Rochester,Minnesota,United States,55905[14]Washington University School of Medicine,Saint Louis,Missouri,United States,63110[15]Astera Cancer Care,East Brunswick,New Jersey,United States,08816[16]Willamette Valley Cancer Institute and Research Center,Eugene,Oregon,United States,97401[17]University of Pittsburgh Medical Center,Pittsburgh,Pennsylvania,United States,15232[18]Sarah Cannon Research Institute,Nashville,Tennessee,United States,37203[19]Texas Oncology P.A.,Austin,Texas,United States,78745[20]Oncology Consultants - Texas,Houston,Texas,United States,77030[21]Virginia Cancer Specialists,Fairfax,Virginia,United States,22031[22]Instituto Alexander Fleming,Buenos Aires,Argentina,C1428ANZ[23]Centro Oncológico Korben,Ciudad Autónoma de Buenos Aires,Argentina,C1426AGE[24]Hospital Privado Centro Medico de Cordoba,Cordoba,Argentina,X5016KEH[25]Centro Oncologico Riojano Integral (Cori),La Rioja,Argentina,F5300COE[26]Clínica Viedma,Viedma,Argentina,R8500ACE[27]Flinders Medical Centre,Bedford Park,Australia,5042[28]Austin Hospital,Heidelberg,Australia,3084[29]Cabrini Medical Centre,Malvern,Australia,3144[30]St John of God Hospital Murdoch,Murdoch,Australia,6150[31]Sir Charles Gairdner Hospital,Nedlands,Australia,6009[32]Westmead Hospital,Westmead,Australia,2145[33]Southern Medical Day Care Centre,Wollongong,Australia,2500[34]Princess Alexandra Hospital,Woolloongabba,Australia,4102[35]Cliniques Universitaires Saint-Luc,Brussel,Belgium,1200[36]Grand Hôpital de Charleroi, site Notre Dame,Charleroi,Belgium,6000[37]UZ Leuven,Leuven,Belgium,3000[38]Clinique Saint Pierre,Ottignies,Belgium,1340[39]Algemeen Ziekenhuis Delta,Roeselare,Belgium,8800[40]Fundacao Pio XII,Barretos,Brazil,14784-400[41]Cetus Oncologia,Belo Horizonte,Brazil,30110-017[42]Ynova Pesquisa Clinica,Florianopolis,Brazil,88020-210[43]Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda,Ijui,Brazil,98700-000[44]Liga Norte Riograndense Contra O Cancer,Natal,Brazil,59062-000[45]UPCO Unidade de Pesquisa Clinica em Oncologia,Pelotas,Brazil,96020 080[46]Irmandade Santa Casa de Misericordia de Porto Alegre,Porto Alegre,Brazil,90020-090[47]União Brasileira de Educação e Assistência-Hospital São Lucas da PUCRS,Porto Alegre,Brazil,90610-000[48]Ministerio da Saude - Instituto Nacional do Cancer,Rio De Janeiro,Brazil,20231-050[49]Oncoclínicas Rio de Janeiro S.A.,Rio de Janeiro,Brazil,22250-905[50]Instituto D'Or de Pesquisa e Ensino (IDOR),Rio de Janeiro,Brazil,22281-100[51]Fundacao Faculdade de Medicina - Instituto do Cancer do Estado de Sao Paulo,Sao Paulo,Brazil,01246-000[52]Fundação Antônio Prudente - A.C. Camargo Cancer Center,Sao Paulo,Brazil,01509900[53]Núcleo de Pesquisa São Camilo,Sao Paulo,Brazil,04014-002[54]IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado,Sorocaba,Brazil,18030-075[55]Hospital Evangélico de Cachoeiro de Itapemirim,Vitoria,Brazil,29308-014[56]William Osler Health System,Brampton,Ontario,Canada,L6R 3J7[57]Juravinski Cancer Centre,Hamilton,Ontario,Canada,L8V 5C2[58]Sichuan Cancer Hospital,Chengdu, China, 610041
研究目的：
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions [Exon 19del] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
